FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2103286082> ?p ?o ?g. }

• W2103286082 endingPage "38" @default.
• W2103286082 startingPage "31" @default.
• W2103286082 abstract "Background Conventional anticoagulant treatment for acute deep vein thrombosis (DVT) effectively prevents thrombus extension and recurrence, but does not dissolve the clot, and many patients develop post-thrombotic syndrome (PTS). We aimed to examine whether additional treatment with catheter-directed thrombolysis (CDT) using alteplase reduced development of PTS. Methods Participants in this open-label, randomised controlled trial were recruited from 20 hospitals in the Norwegian southeastern health region. Patients aged 18–75 years with a first-time iliofemoral DVT were included within 21 days from symptom onset. Patients were randomly assigned (1:1) by picking lowest number of sealed envelopes to conventional treatment alone or additional CDT. Randomisation was stratified for involvement of the pelvic veins with blocks of six. We assessed two co-primary outcomes: frequency of PTS as assessed by Villalta score at 24 months, and iliofemoral patency after 6 months. Analyses were by intention to treat. This trial is registered at ClinicalTrials.gov, NCT00251771. Findings 209 patients were randomly assigned to treatment groups (108 control, 101 CDT). At completion of 24 months' follow-up, data for clinical status were available for 189 patients (90%; 99 control, 90 CDT). At 24 months, 37 (41·1%, 95% CI 31·5–51·4) patients allocated additional CDT presented with PTS compared with 55 (55·6%, 95% CI 45·7–65·0) in the control group (p=0·047). The difference in PTS corresponds to an absolute risk reduction of 14·4% (95% CI 0·2–27·9), and the number needed to treat was 7 (95% CI 4–502). Iliofemoral patency after 6 months was reported in 58 patients (65·9%, 95% CI 55·5–75·0) on CDT versus 45 (47·4%, 37·6–57·3) on control (p=0·012). 20 bleeding complications related to CDT included three major and five clinically relevant bleeds. Interpretation Additional CDT should be considered in patients with a high proximal DVT and low risk of bleeding. Funding South-Eastern Norway Regional Health Authority; Research Council of Norway; University of Oslo; Oslo University Hospital." @default.
• W2103286082 created "2016-06-24" @default.
• W2103286082 creator A5007327694 @default.
• W2103286082 creator A5007335292 @default.
• W2103286082 creator A5010765744 @default.
• W2103286082 creator A5015526318 @default.
• W2103286082 creator A5017854442 @default.
• W2103286082 creator A5021697341 @default.
• W2103286082 creator A5023041920 @default.
• W2103286082 creator A5025089328 @default.
• W2103286082 creator A5046050533 @default.
• W2103286082 creator A5049802776 @default.
• W2103286082 creator A5050606530 @default.
• W2103286082 creator A5073390769 @default.
• W2103286082 date "2012-01-01" @default.
• W2103286082 modified "2023-10-18" @default.
• W2103286082 title "Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): a randomised controlled trial" @default.
• W2103286082 cites W1491789777 @default.
• W2103286082 cites W1684164902 @default.
• W2103286082 cites W1968406183 @default.
• W2103286082 cites W1980669153 @default.
• W2103286082 cites W1984052453 @default.
• W2103286082 cites W2006671909 @default.
• W2103286082 cites W2014956686 @default.
• W2103286082 cites W2029339882 @default.
• W2103286082 cites W2052174005 @default.
• W2103286082 cites W2054515228 @default.
• W2103286082 cites W2059565225 @default.
• W2103286082 cites W2068802530 @default.
• W2103286082 cites W2072975396 @default.
• W2103286082 cites W2086444959 @default.
• W2103286082 cites W2102161554 @default.
• W2103286082 cites W2110168457 @default.
• W2103286082 cites W2126286036 @default.
• W2103286082 cites W2126567924 @default.
• W2103286082 cites W2130010985 @default.
• W2103286082 cites W2139511851 @default.
• W2103286082 cites W2155162963 @default.
• W2103286082 cites W2156320702 @default.
• W2103286082 cites W2156816596 @default.
• W2103286082 cites W2159553511 @default.
• W2103286082 cites W2160022765 @default.
• W2103286082 cites W2161007136 @default.
• W2103286082 cites W2161541695 @default.
• W2103286082 cites W2165141127 @default.
• W2103286082 cites W2167955183 @default.
• W2103286082 cites W4211026269 @default.
• W2103286082 cites W4294109446 @default.
• W2103286082 doi "https://doi.org/10.1016/s0140-6736(11)61753-4" @default.
• W2103286082 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22172244" @default.
• W2103286082 hasPublicationYear "2012" @default.
• W2103286082 type Work @default.
• W2103286082 sameAs 2103286082 @default.
• W2103286082 citedByCount "774" @default.
• W2103286082 countsByYear W21032860822012 @default.
• W2103286082 countsByYear W21032860822013 @default.
• W2103286082 countsByYear W21032860822014 @default.
• W2103286082 countsByYear W21032860822015 @default.
• W2103286082 countsByYear W21032860822016 @default.
• W2103286082 countsByYear W21032860822017 @default.
• W2103286082 countsByYear W21032860822018 @default.
• W2103286082 countsByYear W21032860822019 @default.
• W2103286082 countsByYear W21032860822020 @default.
• W2103286082 countsByYear W21032860822021 @default.
• W2103286082 countsByYear W21032860822022 @default.
• W2103286082 countsByYear W21032860822023 @default.
• W2103286082 crossrefType "journal-article" @default.
• W2103286082 hasAuthorship W2103286082A5007327694 @default.
• W2103286082 hasAuthorship W2103286082A5007335292 @default.
• W2103286082 hasAuthorship W2103286082A5010765744 @default.
• W2103286082 hasAuthorship W2103286082A5015526318 @default.
• W2103286082 hasAuthorship W2103286082A5017854442 @default.
• W2103286082 hasAuthorship W2103286082A5021697341 @default.
• W2103286082 hasAuthorship W2103286082A5023041920 @default.
• W2103286082 hasAuthorship W2103286082A5025089328 @default.
• W2103286082 hasAuthorship W2103286082A5046050533 @default.
• W2103286082 hasAuthorship W2103286082A5049802776 @default.
• W2103286082 hasAuthorship W2103286082A5050606530 @default.
• W2103286082 hasAuthorship W2103286082A5073390769 @default.
• W2103286082 hasConcept C126322002 @default.
• W2103286082 hasConcept C141071460 @default.
• W2103286082 hasConcept C168563851 @default.
• W2103286082 hasConcept C2778555097 @default.
• W2103286082 hasConcept C2778959117 @default.
• W2103286082 hasConcept C2779581417 @default.
• W2103286082 hasConcept C2780868729 @default.
• W2103286082 hasConcept C2781362458 @default.
• W2103286082 hasConcept C500558357 @default.
• W2103286082 hasConcept C71924100 @default.
• W2103286082 hasConceptScore W2103286082C126322002 @default.
• W2103286082 hasConceptScore W2103286082C141071460 @default.
• W2103286082 hasConceptScore W2103286082C168563851 @default.
• W2103286082 hasConceptScore W2103286082C2778555097 @default.
• W2103286082 hasConceptScore W2103286082C2778959117 @default.
• W2103286082 hasConceptScore W2103286082C2779581417 @default.
• W2103286082 hasConceptScore W2103286082C2780868729 @default.
• W2103286082 hasConceptScore W2103286082C2781362458 @default.
• W2103286082 hasConceptScore W2103286082C500558357 @default.

• next